Tests AHB-121 injection in healthy adults and people with chronic hepatitis B
Tests AHB-121 injection for safety in healthy adults and chronic hepatitis B patients.
Plain-language title generated from the registry record
Registry title: A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adults and adults with chronic hepatitis B to test the safety and effects of AHB-121 injection.
- Age
- 18 to 65 years
- Sex
- All sexes
- Disease stage
- Two groups: healthy people with normal screening results, and people with chronic hepatitis B whose HBsAg, HBV DNA, ALT and HBeAg meet certain indicators.
- Earlier treatment
- People cannot join if they took part in another trial or received an investigational drug within the specified time before screening.
- Biomarker or test result
- For people with chronic hepatitis B: HBsAg, HBV DNA, ALT and HBeAg must meet certain indicators. The record does not give the values.
Main reasons for not taking part
- Serious systemic disease or past malignant tumor
- Other liver diseases, liver dysfunction, significant liver fibrosis or cirrhosis, or liver cell carcinoma
- Autoimmune disease or disease with a risk of immune activation
- Solid organ or stem cell transplant before screening
- Positive pregnancy test at screening
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07884864, who can take part
Where in China
- Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ausper Biopharma Co., Ltd.
- Trial code
- NCT07884864
- Record updated
- 21 October 2026
- Original description
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AHB-121 injection in healthy and chronic hepatitis B participants.Read full original descriptionShow less
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AHB-121 Injection in Healthy and Chronic Hepatitis B Participants
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AHB-121 injection in healthy and chronic hepatitis B participants.
Inclusion: Sign the informed consent form and be able to complete the research as required; Age and weight meet the requirements; During the screening, the results of physical examination, vital signs, laboratory tests, electrocardiogram, etc. are normal or have no clinical significance(healthy individuals); Take effective contraceptive measures as required; During the screening, HBsAg, HBV DNA, ALT, and HBeAg meet certain indicators (CHB participants).
Exclusion: Participate in other clinical trials or receive investigational drug treatment within the specified time before screening, and have received related drug; Have received solid organ transplantation or hematopoietic stem cell transplantation before screening; Have positive urine drug screening or alcohol breath test during screening; have donated blood or lost a large amount of blood before screening, received blood transfusion, or have a blood donation plan during the study; Have a serious systemic disease or a history of malignant tumor; Have other liver diseases besides chronic HBV infection, or have liver dysfunction, significant liver fibrosis/ cirrhosis, history of liver cell carcinoma or suspected cases; Have autoimmune diseases or diseases with a risk of immune activation; Have a questionable allergy to the test drugs and their components, or have an allergic constitution; Have acute infection, major trauma or major surgery with clinical significance that has not fully recovered within the specified time before screening, or have a surgical plan during the study; Have positive screening for related infectious diseases; Have a history of drug abuse or alcoholism; or have a large amount of smoking before screening and cannot stop during the study; Have a history of fainting or hemisomnia, difficulty in blood collection, or inability to tolerate venipuncture blood collection; Have abnormal laboratory tests, vital signs or electrocardiogram results during screening and have clinical significance as judged by the researcher; Have consumed caffeine, xanthine-containing foods or beverages, or engaged in intense exercise within the specified time before administration, or have been unable to stop during the study; Have a positive pregnancy test during screening; Abnormal skin at the injection site; The researcher considers that there are other factors that make one unsuitable to participate in this trial.